SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank83
5Y CAGR-3.5%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

5Y CAGR
-3.5%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$17.67M+160.9%
2024$-28.99M+24.0%
2023$-38.13M-152.2%
2022$-15.12M+0.5%
2021$-15.20M-171.9%
2020$21.14M+356.7%
2019$-8.23M-